Clinical Trials Logo

Low-grade Gliomas clinical trials

View clinical trials related to Low-grade Gliomas.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02285439 Active, not recruiting - Clinical trials for Soft Tissue Neoplasms

Study of MEK162 for Children With Low-Grade Gliomas

Start date: May 4, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to study the drug MEK162 in children with a brain tumor call low-grade glioma, as well as in children with other tumors in which a specific growth signal is abnormally turned on. The main questions it aims to answer are: What is the correct dose of MEK162 in children? What are the side effects of MEK162 in children? Is MEK162 effective in children with low-grade glioma? Participants on the study receive MEK162 by mouth twice daily for up to 2 years.

NCT ID: NCT00517959 Active, not recruiting - Craniopharyngioma Clinical Trials

SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors

SCRT
Start date: May 2001
Phase: Phase 3
Study type: Interventional

Brain tumours are the commonest solid tumours in children and the second most common neoplasms overall in this patient population. Radiotherapy plays an important part in the management in a majority of these tumours. While the cure rates of these tumours, especially the benign and low grade ones are quite encouraging, the treatment itself may lead to some late sequelae, which could have significant implications in the quality of life in these long-term survivors. Stereotactic conformal radiotherapy (SCRT) is a modern high-precision radiotherapy technique, which reduces the volume of normal brain irradiated and has the capability to minimise the doses to critical structures. The present study is designed to prospectively estimate the incidence and severity of neuropsychological, cognitive and neuroendocrine dysfunction following radiotherapy delivered with conventional and stereotactic techniques and would be one of the most comprehensive studies providing very important longitudinal and reliable data regarding these sequelae. The study involving 200 patients would be to the best of our knowledge not only the largest ever study conducted so far but also the only randomised trial assessing these sequelae in patients receiving focal brain irradiation. The study also examines whether the physical advantages of modern technological progress translate in clinical benefit. This could have significant implications in the radiotherapeutic management of children and young adults with brain tumours. The study is unique in design in terms of evaluating the efficacy of SCRT with respect to conventional radiotherapy in terms of long term tumour control and treatment related complications.